



CLAIMS


1. A compound of formula (A), (B) or (C):



(A)



(B)



(C)

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof,
5 or a mixture of same.

2. A compound according to claim 1, or a stereoisomer, a tautomer, an N-oxide, a
hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable
salt thereof, or a mixture of same, for use in the treatment or prophylaxis of a
10 disease.

3. A compound according to claim 2, or a stereoisomer, a tautomer, an N-oxide, a
hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable
salt thereof, or a mixture of same, wherein said disease is a disease of uncontrolled
15 cell growth, proliferation and/or survival, an inappropriate cellular immune
response, or an inappropriate cellular inflammatory response, particularly in which
the uncontrolled cell growth, proliferation and/or survival, inappropriate cellular
immune response, or inappropriate cellular inflammatory response is mediated by
the mitogen-activated protein kinase (MEK-ERK) pathway, more particularly in
20 which the disease of uncontrolled cell growth, proliferation and/or survival,
inappropriate cellular immune response, or inappropriate cellular inflammatory
response is a haematological tumour, a solid tumour and/or metastases thereof,

e.g. leukaemias and myelodysplastic syndrome, malignant lymphomas, head and neck tumours including brain tumours and brain metastases, tumours of the thorax including non-small cell and small cell lung tumours, gastrointestinal tumours, endocrine tumours, mammary and other gynaecological tumours, urological tumours including renal, bladder and prostate tumours, skin tumours, and sarcomas, and/or metastases thereof.

4. A pharmaceutical composition comprising a compound according to claim 1, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, and a pharmaceutically acceptable diluent or carrier.


5. A pharmaceutical combination comprising :

- one or more compounds according to claim 1, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same;


and

- one or more agents selected from : a taxane, such as Docetaxel, Paclitaxel, or Taxol; an epothilone, such as Ixabepilone, Patupilone, or Sagopilone; Mitoxantrone; Prednisolone; Dexamethasone; Estramustin; Vinblastin; Vincristin; Doxorubicin; Adriamycin; Idarubicin; Daunorubicin; Bleomycin; Etoposide; Cyclophosphamide; Ifosfamide; Procarbazine; Melphalan; 5-Fluorouracil; Capecitabine; Fludarabine; Cytarabine; Ara-C; 2-Chloro-2'-deoxyadenosine; Thioguanine; an anti-androgen, such as Flutamide, Cyproterone acetate, or Bicalutamide; Bortezomib; a platinum derivative, such as Cisplatin, or Carboplatin; Chlorambucil; Methotrexate; and Rituximab.


6. A method of preparing a compound according to claim 1, said method comprising the step of allowing an intermediate compound of formula (A1), (B1) or (C1) :



(A1)



(B1)




(C1)

5

in which Z' represents a group selected from: -C(=O)OH and -C(=O)O-(C₁-C₆-alkyl);

to react with a compound of formula Ib :




Ib

10


thereby giving, upon optional deprotection, a compound of formula (A), (B) or (C) as defined in claim 1.

7. A method of preparing a compound according to claim 1, said method comprising the step of allowing an intermediate compound of general formula (A2), (B2) or (C2):


15



(A2)



(B2)




(C2)

5

in which Q^2 is a leaving group;

to react with a compound of general formula IIa :




IIa

10 in which Y is a substituent which is displaced in a coupling reaction, such as a boronic acid group, or an ester of a boronic acid group ;


thereby giving, upon optional deprotection, a compound of formula (A), (B) or (C), as defined in claim 1.

15


8. A method of preparing a compound according to claim 1, said method comprising the step of conversion of an intermediate compound of formula (A3), (B3) or (C3):



(A3)




(B3)




(C3)

in which Q^1 is a leaving group;


to react with a compound of general formula (A4), (B4) or (C4):



(A4)




(B4)




(C4)

thereby giving, upon optional deprotection, a compound of general formula (A), (B) or (C), as defined in claim 1.


9. A method of preparing a compound according to claim 1, said method comprising the step of conversion of an intermediate compound of formula (A5), (B5) or (C5):



(A5)




(B5)




(C5)

in which Q³ is an optionally protected NH₂-group;


to react with a compound of general formula (A6), (B6) or (C6) :



(A6)




(B6)




(C6)

thereby giving, after reduction of the imine, and upon optional deprotection, a compound of formula (A), (B) or (C), as defined in claim 1.


10. A method of preparing a compound according claim 1, said method comprising the step of conversion of an intermediate compound of formula formula (A7), (B7) or (C7):



(A7)




(B7)




(C7)

10 in which $R^{3'}$ is a leaving group ;


to react with a compound of formula (A8), (B8) or (C8):



(A8)



(B8)



(C8)

15 in which Y is a substituent which is displaced in a coupling reaction, such as a hydrogen atom, or a boronic acid group, or a boronic ester group, for example;

thereby giving a compound of formula (A), (B) or (C), as defined in claim 1.

11. Use of a compound according to claim 1, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, for the prophylaxis or treatment of a disease.

5

12. Use of a compound according to claim 1, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, for the preparation of a medicament for the prophylaxis or treatment of a disease.

10

13. Use according to claim 11 or 12, wherein said disease is a disease of uncontrolled cell growth, proliferation and/or survival, an inappropriate cellular immune response, or an inappropriate cellular inflammatory response, particularly in which the uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune response, or inappropriate cellular inflammatory response is mediated by the mitogen-activated protein kinase (MEK-ERK) pathway, more particularly in which the disease of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune response, or inappropriate cellular inflammatory response is a haematological tumour, a solid tumour and/or metastases thereof, e.g. leukaemias and myelodysplastic syndrome, malignant lymphomas, head and neck tumours including brain tumours and brain metastases, tumours of the thorax including non-small cell and small cell lung tumours, gastrointestinal tumours, endocrine tumours, mammary and other gynaecological tumours, urological tumours including renal, bladder and prostate tumours, skin tumours, and sarcomas, and/or metastases thereof.

25


14. A compound of formula (A1), (A2), (A3), (A5), (A7), (B1), (B2), (B3), (B5), (B7), (C1), (C2), (C3), (C5) or (C7) as defined in claims 6, 7, 8, 9, and 10.

30

15. A compound of formula (A1), (A2), (A3), (A4), (A5), (A6), (A7), (A8), (B1), (B2), (B3), (B4), (B5), (B6), (B7), (B8), (C1), (C2), (C3), (C4), (C5), (C6), (C7) or (C8) as defined in claims 6, 7, 8, 9, and 10, for the preparation of a compound of formula (A), (B) or (C), respectively.

CLAIMS

1. A compound of formula (B):



(B)

or an N-oxide, a hydrate, a solvate, or a salt thereof.

2. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of a disease.

3. A compound for use according to claim 2, or a pharmaceutically acceptable salt thereof, wherein said disease is a disease of uncontrolled cell growth, proliferation and/or survival, an inappropriate cellular immune response, or an inappropriate cellular inflammatory response, particularly in which the uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune response, or inappropriate cellular inflammatory response is mediated by the mitogen-activated protein kinase (MEK-ERK) pathway, more particularly in which the disease of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune response, or inappropriate cellular inflammatory response is a haematological tumour, a solid tumour and/or metastases thereof, *e.g.* leukaemias and myelodysplastic syndrome, malignant lymphomas, head and neck tumours including brain tumours and brain metastases, tumours of the thorax including non-small cell and small cell lung tumours, gastrointestinal tumours, endocrine

tumours, mammary and other gynaecological tumours, urological tumours including renal, bladder and prostate tumours, skin tumours, and sarcomas, and/or metastases thereof.

5 4. A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.


5. A pharmaceutical combination comprising :

10 - the compound according to claim 1, or a pharmaceutically acceptable salt thereof;

and

- one or more agents selected from : a taxane, such as Docetaxel, Paclitaxel, or Taxol; an epothilone, such as Ixabepilone, Patupilone, or Sagopilone; Mitoxantrone;
15 Predinisolone; Dexamethasone; Estramustin; Vinblastin; Vincristin; Doxorubicin; Adriamycin; Idarubicin; Daunorubicin; Bleomycin; Etoposide; Cyclophosphamide; Ifosfamide; Procarbazine; Melphalan; 5-Fluorouracil; Capecitabine; Fludarabine; Cytarabine; 2-Chloro-2'-deoxyadenosine; Thioguanine; an anti-androgen, such as Flutamide, Cyproterone acetate, or Bicalutamide; Bortezomib; a platinum
20 derivative, such as Cisplatin, or Carboplatin; Chlorambucil; Methotrexate; and Rituximab.


6. A method of preparing a compound according to claim 1, said method
25 comprising the step of allowing an intermediate compound of formula (B1):



(B1)

in which Z' represents a group selected from: -C(=O)OH and -C(=O)O-(C₁-C₆-alkyl);

to react with a compound of formula **1b** :




5

1b

thereby giving, upon optional deprotection, a compound of formula (B) as defined in claim 1.

7. A method of preparing a compound according to claim 1, said method comprising the step of allowing an intermediate compound of general formula (B2):




(B2)

in which Q² is a halogen atom;

15

to react with a compound of general formula **IIa** :




IIa

in which Y is a substituent which is displaced in a coupling reaction selected from a boronic acid group, or an ester of a boronic acid group ;

20

thereby giving, upon optional deprotection, a compound of formula (B), as defined in claim 1.


8. A method of preparing a compound according to claim 1, said method comprising the step of conversion of an intermediate compound of formula (B3):



(B3)

in which Q¹ is a halogen atom;


to react with a compound of general formula (B4):



(B4)

thereby giving, upon optional deprotection, a compound of general formula (B) , as defined in claim 1.


9. A method of preparing a compound according to claim 1, said method comprising the step of conversion of an intermediate compound of formula (B5):



(B5)

in which Q^3 is a NH_2 -group;

- 5 to react with a compound of general formula (B6):




(B6)

thereby giving, after reduction of the imine, and upon optional deprotection, a compound of formula (B), as defined in claim 1.

10


10. A method of preparing a compound according claim 1, said method comprising the step of conversion of an intermediate compound of formula formula (B7) :



(B7)

in which $R^{3'}$ is a bromine atom;

to react with a compound of formula (B8):



(B8)

in which Y is a substituent which is displaced in a coupling reaction selected from a hydrogen atom, or a boronic acid group, or a boronic ester group;

10 thereby giving a compound of formula (B), as defined in claim 1.

11. Use of the compound according to claim 1, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the prophylaxis or treatment of a disease wherein said disease is a disease of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune response, or
15 inappropriate cellular inflammatory response is a haematological tumour, a solid tumour and/or metastases thereof, specifically leukaemias and myelodysplastic syndrome, malignant lymphomas, head and neck tumours including brain tumours and brain metastases, tumours of the thorax including non-small cell and small cell
20 lung tumours, gastrointestinal tumours, endocrine tumours, mammary and other gynaecological tumours, urological tumours including renal, bladder and prostate tumours, skin tumours, and sarcomas, and/or metastases thereof.

12. A compound of formula (B1), (B2), (B3), (B5), as defined in claims 6, 7, 8, and
25 9.